AT THE PEAK of the Covid-19 pandemic, the one thing that had become ubiquitous was the RT-PCR test. Scenes of swabs being thrust into the nose and throat had practically become part of regular life. What that also did was provide a fillip to the financials of diagnostic companies that were doing the tests. The possibility of a new revenue and profit stream also encouraged a herd of other entities to jump into the diagnostics fray. But now, as the pandemic wanes and RT-PCR testing peters to a trickle, the past few quarters have seen profits dip for leading diagnostic players. For example, market leader Dr Lal PathLabs, headquartered in New Delhi, recorded a 26.5 per cent dip in consolidated net profit to ₹61.3 crore in Q4FY22 from ₹83.4 crore in Q4FY21. Likewise, Mumbai-headquartered Metropolis Healthcare reported a 34.8 per cent decline in consolidated net profit at ₹39.99 crore in Q4FY22 compared to ₹61.35 crore in Q4FY21.
According to a report by Antique Stock Broking, margins reported during FY21 at the peak of Covid-19 will not be repeated anytime soon, plus there is other impact, too. “We expect negative operating leverage and return ratios such as return on capital employed (ROCE) to remain under check at 2526 per cent for both [Dr Lal and Metropolis], a decline in comparison to the pre-pandemic range of around 33 per cent,” says the report released in September. Another report from Credit Suisse, penned by research analysts Sayantan Maji and Anubhav Aggarwal, says that high competitive intensity could halve industry ROCE. The report says: “We expect ROCE to settle down to around 20-25 per cent by FY27E, implying Ebitda margin of around 20 per cent. Ebitda margin of Dr Lal and Metropolis has already declined by 300 bps (vs pre-Covid-19) to 23 per cent, but we expect it to steadily contract by a further 300-400 bps.”
This story is from the October 30, 2022 edition of Business Today India.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the October 30, 2022 edition of Business Today India.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Pension Scheme - Safety Net
The move to introduce the UPS has evoked mixed reactions. Analysts believe its funding will have limited impact on the fiscal math
The Reit Choice?
Real Estate Investment Trusts (Reits) Are Gaining Traction As Interest Rates Stabilise. But Returns Could Be Affected By Adverse Economic Conditions And Market Volatility
CORPORATE - Calling to Account
The sudden exit of Byju's auditor BDO marks the latest in a long series of setbacks for the edtech firm
EMPLOYMENT: Skills Push
The skill development ministry plans to partner with the UGC to improve the employability of undergraduates
Building on a Vision
L&T'S CHAIRMAN EMERITUS A. M. NAIK HAS BUILT A MAMMOTH ENTERPRISE THAT IS BUILDING A NEW INDIA, FROM ITS METRO RAIL SYSTEMS TO THE RAM TEMPLE
"KYS more important than KYC"
Vijay Kedia is a renowned equity investor; the value of his listed portfolio stands at around ₹1,750 crore
ROXX STAR
THE THAR ROXX COMBINES LUXURY WITH PERFORMANCE TO MAKE A STRONG STATEMENT IN THE MID-SIZE SUV SEGMENT
HIT THE GROUND RUNNING
Smartwatches have become indispensable tools for runners, offering real-time insights into pace, distance, heart rate, and more. Here are a few you can consider
TURNING THE TABLES
INDIA'S FURNITURE MARKET IS POISED FOR A GLOBAL TAKE-OFF. ALREADY, A HOST OF GLOBAL BRANDS HAVE MADE THE COUNTRY THEIR HOME, BUT INDIAN COMPANIES ARE NOT TOO FAR BEHIND
THE EVOLUTION OF ATHERA
IDENTIFYING OPPORTUNITIES IN ADVANCE HAS STOOD THIS BENGALURU-BASED VC FUND IN GOOD STEAD. NOW, WITH A HEIGHTENED FOCUS ON TECHNOLOGY, IT WANTS TO SUSTAIN THE SUCCESS